Quote this publication Share Print

TREVICTA (paliperidone), antipsychotic

PSYCHIATRY - New medicinal product
Opinions on drugs - Posted on Dec 12 2016

Reason for request


No clinical benefit demonstrated for a 3-monthly injection when compared with monthly injections of paliperidone in the maintenance treatment of schizophrenia.

  • TREVICTA, a 3-monthly injection, has Marketing Authorisation in the maintenance treatment of schizophrenia in adult patients who are clinically stable on monthly paliperidone palmitate injections. 
  • The non-inferiority of 3-monthly injections of paliperidone palmitate compared with monthly injections has been demonstrated, without improvement in safety or quality of life.
  • TREVICTA is to be used only after the patient has been adequately treated with 1-monthly paliperidone palmitate injections, preferably for four months or more, in situations where spacing of the injections would not be detrimental to the patient’s regular monitoring, which is at least monthly and which is not limited to the single administration of the medicinal product

Clinical Benefit



Clinical Added Value

no clinical added value


Therapeutic use


Contact Us

Évaluation des médicaments